(Q42999431)

English

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

scientific article published in July 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

Patrizia Pontisso

1 reference

ORCID Public Data File 2021

Alfredo Alberti

1 reference

ORCID Public Data File 2021

author name string

Cavalletto L

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Chemello L

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Donada C

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Casarin P

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Belussi F

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Bernardinello E

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Marino F

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Pontisso P

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gatta A

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alberti A

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 July 2000

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

128-134

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C: re-treatment with alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980169-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(00)80169-5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42999431&oldid=1976325020"